medigraphic.com

2001, Número 3

<< Anterior Siguiente >>

Arch Cardiol Mex 2001; 71 (3)


Lipoproteína (a), ¿es un factor de riesgo en la enfermedad aterotrombótica coronaria?

Peña A, Izaguirre R, Anglés-Cano E

Idioma: Español
Referencias bibliográficas: 44
Paginas: 188-192
Archivo PDF: 71.47 Kb.


FRAGMENTO

A pesar de que numerosos estudios in vitro e in vivo confirman la participación de la Lp(a) en los procesos fisiopatológicos de la aterosclerosis y de que los estudios retrospectivos consistentemente confirman la asociación entre Lp(a) y la enfermedad isquémica coronaria y cerebral, algunos estudios prospectivos han reportado resultados inconsistentes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gaubatz JW, Heideman C, Gotto AM, Morrisett JD, Dahlen GH: Human plasma lipoprotein(a)-structural properties. J Biol Chem 1983; 258: 4582-4589.

  2. Kamboch ML, Ferrel RE, Kottke BA: Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Gent 1991; 49: 1063-1074.

  3. Utermann G, Menzel HJ, Kraft G, Duba HC, Kemmler HG, Seitz C: LP(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80: 458-465.

  4. De Bruin TWA, van Barlingen H, van Linde-Sibenius, Trip M, van Vuurst de Vries AR, Akveld MJ, Erkelens WD: Lipoprotein (a) and apolipoprotein B plasma concentrations in hypotyroid, euthiroid and hyperthiroid subjects. J Clin Endocrinol Metab 1993; 76: 121-126.

  5. Haenggi W, Reisen W, Birkhaeuser MH: Postmenopausal hormone replacement therapy with tibolone decreases serum lipoprotein(a). Eur J Clin Biochem 1993; 31: 645-650.

  6. Henriksson P, Angelin B, Berglund D: Hormonal regulation of serum Lp(a) levels. J Clin Invest 1992; 89: 1166-1171.

  7. Soma MR, Meschia M, Bruschi F, Morriset JD, Paoletti R, Fumagalli R, Cosignani P: Hormonal agents used in lowering lipoprotein(a). Chem Physics Lipids 1994; 67: 345-350.

  8. Taskinen MR, Puolakka J, Pyorala T, Luotola H, Bjaorn M, Kaarianen J, et al: Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuos estrogen-progestin regimens. Arterioscler Thromb Vasc Biol 1996; 16: 1215-1221.

  9. Albers JJ, Taggart HM, Applebaum-Bowden D, Haffner S, Chesnut CH, Hazzard WR: Reduction on lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanazol. Biochim Biophys Acta 1984; 795: 293-296.

  10. Eden F, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA: Growth hormone treatment of growth hormone-deficient adults result in a marked increase in Lp(a) and HDL cholesterol concentrations. Artherioscler Thromb 1993; 13: 296-301.

  11. Anglés-Cano E, Hervio L, Loyau S: Lipoprotéine, hypofibrinolyse et athérothrombose, quo vadis? Sang Thrombose Vaisseaux 1995; 7: 315-322.

  12. Berg K: Lp(a) Lipoprotein: an overview. Chem Phys Lipids 1992; 67/68: 9-18.

  13. Dahlén GH: Lp(a) Lipoprotein in cardiovascular disease. Atherosclerosis 1994; 108: 111-126.

  14. Brown MS, Goldstein JL: Plasma lipoproteins: teaching old dogmas new tricks. Nature 1987; 330: 113-114.

  15. Anglés-Cano E, Hervio L, Rouy D: Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type Plasminogen activator. Chem Phys Lipids 1994; 67/68: 369-380.

  16. MBewu AD, Durrington PN: Lipoprotein(a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990; 85: 1-14.

  17. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF: A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 1989; 339; 301-303.

  18. Nachman RL. Thrombosis and atherogenesis: molecular conections. Blood 1992; 79: 1897-1906.

  19. Peynet J, Beauldeux JL, Wolmant F, Flourie F, Giraudeaux V, Vicaut E, Launay JM: Apolipoprotein (a) size polymorphism in young adults with ischemic stroke. Atherosclerosis 1999; 142: 233-239.

  20. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, et al: The association between LP(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986; 62: 249-257.

  21. Dahlén GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM: Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758-765.

  22. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H: Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990; 301: 1248-1251.

  23. Cremer P, Nagel D, Labrot B: LDL cholesterol and other risk factor: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444-453.

  24. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johson AM, et al: Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994: 343: 75-79.

  25. Schaefer EJ, Lamon-Fava S, Jenner JL, Mc Namara JR, Ordovas JM, Davis CE, et al: Lipoprotein (a) levels and risk of coronary heart disease in men. The lipid research clinics coronary primary prevention trial. JAMA 1994; 271: 999-1003.

  26. Bostom A, Gagnon D, Cupples A, Wilson P, Jenner J, Ordovas J, et al: Prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994; 90: 1688-1699.

  27. Dahlén GH, Stenlund H: Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet 1997; 52: 272-280.

  28. von Eckardstein A, Schulte H, Cullen P, Assmann G: Lipoprotein (a) further increases the risk of coronary events in men with high global cardiovascular risk. Am Coll Cardiol 2001; 37: 434-439.

  29. Jauhiainen M, Koskinen P, Ehnholm, Frick MH, Manttari M, Manninen V, Huttunen JK: Lipoprotein (a) and coronary heart disease risk. A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.

  30. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-2199.

  31. Rouy D, Koschinsky ML, Fleury V, Chapman MJ, Anglés-Cano E: Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry 1992; 31: 6333-6339.

  32. Craig W, Neveux M, Palomaki G, Cleveland M, Haddow J: Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998; 44: 2301-2306.

  33. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al: Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finish population based study . Atherosclerosis 1994; 106: 9-19.

  34. Danesh J, Collins Rory, Peto Richard: Lipoprotein(a) and coronary heart disease meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085.

  35. Kronenberg F, Kronenberg MF, Kiechl S, Trenwalder E, Santer P, Oberhollenzer F, et al: Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999; 100: 1154-1160.

  36. Anglés-Cano E: High antifibrinolytic activity of lipoprotein(a) containing small apolipoprotein(a) isoforms. Circulation 2000; 102: E184.

  37. Soulat T, Loyau S, Baudouis V, Maisonneuve L, Hurtaud-Roux MF, Schlegel N, et al: Evidence that modifications of Lp(a) in vivo inhibits plasmin formation on fibrin. Thromb Haemost 1999; 82: 121-127.

  38. Fleury V, Anglés-Cano E: Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991: 30: 7630-7638.

  39. Fleury V, Loyau S, Lijnen HR, Nieuwenhuizen W, Anglés-Cano E: Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface. Eur J Biochem 1993; 216: 549-556.

  40. Rouy D, Laplaud PM, Saboreau M, Anglés-Cano E: Hedgehog lipoprotein(a) is a modulator of activation of plasminogen at the fibrin surface. An in vitro study. Arterioscler Thromb 1992; 12: 146-154.

  41. Anglés-Cano E: A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators. Annal Biochem 1986; 43: 129-132.

  42. Rouy D, Grailhe P, Nigon F, Chapman J, Anglés-Cano E: Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb 1991; 11: 629-638.

  43. Hervio L, Durlach V, Girard-Globa A, Anglés-Cano E: Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry 1995; 34: 13353-13358.

  44. Anglés-Cano E, Hervio L, Loyau S: Relevance of lipoprotein(a) in cardiovascular disease: methodological approaches. Fibrinolysis 1993; 7: 66-68.




2020     |     www.medigraphic.com